By Billy Candra 
Physicians dedicated to the long-term well-being of childhood cancer survivors must now integrate a deeper understanding of genetic predispositions alongside established treatment exposures when assessing the risk for secondary cancers. This critical insight, emanating from groundbreaking research conducted by scientists at St. Jude Children’s Research Hospital, provides the first quantitative attribution of various factors contributing to this formidable challenge. Published in the prestigious journal The Lancet Oncology, the study underscores that while lifesaving therapies are paramount, the individual genetic makeup of a survivor plays a far more significant and often underappreciated role in subsequent cancer development than previously understood, particularly for certain cancer types.
The journey through childhood cancer treatment is often a testament to medical advancement and human resilience. Over the past several decades, dramatic improvements in diagnostic techniques and therapeutic strategies have transformed what was once a near-certain death sentence into a highly curable disease for a significant majority of pediatric patients. Survival rates for childhood cancers, which hovered around 10-20% in the mid-20th century, have now surpassed 80% for many types. This remarkable progress, however, has brought into sharp focus a new set of challenges: the long-term health consequences faced by these survivors. Among the most devastating of these late effects are secondary cancers, which tragically emerge as the leading cause of mortality for individuals who have successfully navigated their initial diagnosis and treatment.
The Enduring Challenge of Childhood Cancer Survivorship
For a growing population of childhood cancer survivors, the "cure" often comes with a significant cost. The aggressive treatments necessary to eradicate pediatric malignancies—including chemotherapy, radiation therapy, and surgery—can inflict collateral damage on healthy tissues and organs, manifesting years or even decades later. These late effects can range from cardiovascular problems and endocrine dysfunction to cognitive impairments and, critically, the development of new, distinct cancers unrelated to their primary diagnosis. Historically, the focus of long-term follow-up care for these survivors has predominantly been on meticulously tracking their exposure to specific treatment modalities, such as cumulative doses of radiation or particular chemotherapeutic agents, to predict and mitigate these risks. While this approach has been invaluable, the St. Jude study reveals it to be incomplete.
The St. Jude Lifetime Cohort Study (St. Jude LIFE) and the Childhood Cancer Survivor Study (CCSS) stand as two of the world’s premier and most extensive longitudinal studies dedicated to understanding the long-term health outcomes of childhood cancer survivors. Housed at St. Jude Children’s Research Hospital, these cohorts collectively represent an unparalleled resource, providing deep, comprehensive data on thousands of individuals who have survived pediatric cancer. The St. Jude LIFE study, for instance, offers ongoing clinical assessments, detailed treatment histories, and extensive biological samples, while the CCSS tracks a larger population of survivors across North America. The synergy between these two studies, encompassing over 10,000 survivors with genetic sequencing, allowed the St. Jude scientists to perform an analysis of unprecedented scale and detail, effectively bridging a critical knowledge gap in the field of survivorship research.
Pioneering Research from St. Jude Quantifies Risk Factors
The research team, led by corresponding author Yadav Sapkota, PhD, from St. Jude’s Department of Epidemiology and Cancer Control, embarked on an ambitious endeavor to quantify the relative contributions of various factors to secondary cancer risk at a population level. "We found the burden of second cancer in survivors of childhood cancer is largely contributed by pediatric treatment exposures and genetic predisposition," Dr. Sapkota explained. "We’ve known treatment exposures and genetics were associated with second cancer risk, but this is the first time we’ve been able to attribute the proportion of their contributions to that risk at the population level." This quantification is a pivotal step, moving beyond mere association to understanding the magnitude of influence each factor exerts.
The comprehensive dataset leveraged for this study included not only detailed records of treatment exposures and subsequent health outcomes but also extensive genetic information, lifestyle factors, and the confirmed presence or absence of a secondary cancer. This holistic approach enabled the researchers to disentangle the complex interplay of these variables and provide a clearer picture of their individual and combined impact. Co-author Greg Armstrong, MD, MSCE, chair of the St. Jude Department of Epidemiology and Cancer Control, underscored the unique nature of the data: "This kind of high-impact discovery is only possible in the CCSS and SJLIFE cohorts, that in combination, have more than 12,000 survivors with genetic sequencing." Such a large and well-characterized cohort is indispensable for achieving statistical power sufficient to discern nuanced contributions from multiple risk factors.
Unpacking the Contributions to Secondary Cancer Risk
The study meticulously broke down the proportionate contributions of three primary categories of risk factors: treatment exposures (radiation and chemotherapy), genetic predisposition, and lifestyle factors. The findings offer both validation of existing knowledge and surprising new insights.
Radiation Therapy: The Dominant, Yet Evolving, Factor
Unsurprisingly, radiation exposure emerged as the most significant single contributor to secondary cancer risk, accounting for approximately 40% or more of the overall risk. This finding aligns with decades of research documenting the long-term adverse effects of therapeutic radiation, which, while crucial for eradicating primary tumors, can damage DNA in healthy cells and promote carcinogenesis. For instance, survivors of Hodgkin lymphoma who received mantle field radiation are at significantly elevated risk for breast cancer and lung cancer, while those treated for brain tumors may develop secondary meningiomas or sarcomas.
The historical context of radiation therapy in pediatric oncology is important. Earlier protocols often employed higher doses and broader fields of radiation, given the imperative to achieve a cure when treatment options were fewer. However, awareness of these long-term sequelae has driven a concerted effort in modern oncology to reduce radiation doses, utilize more targeted delivery methods (such as intensity-modulated radiation therapy or proton therapy), or eliminate radiation entirely where other effective treatments are available. The St. Jude study provides robust epidemiological evidence that further supports these ongoing efforts to minimize radiation exposure in pediatric cancer treatment.
Chemotherapy’s Complex and Variable Role
The contribution of chemotherapy to subsequent cancer risk was found to be more varied, ranging from 8% to 35% depending on the specific type of secondary cancer. Chemotherapy encompasses a wide array of drugs with different mechanisms of action, and their late effects can be highly specific. For example, alkylating agents (like cyclophosphamide or ifosfamide) are well-known for their leukemogenic potential, increasing the risk of secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome. Anthracyclines (like doxorubicin) are primarily associated with cardiotoxicity but can also contribute to secondary malignancies. The variability observed in the study underscores the need for continued research into the precise carcinogenic mechanisms of different chemotherapeutic agents and their interaction with other risk factors.
Genetic Predisposition: A Revelatory and Underestimated Force
Perhaps the most striking and paradigm-shifting revelation of the study concerns the significant, and often underestimated, role of genetic predisposition. While the potential late effects of chemotherapy have been extensively documented, the contribution of a survivor’s inherited genetics to their risk of developing a second cancer has been less clearly recognized at a population level. To explore this, the researchers examined hundreds of common genetic variants previously associated with cancer development in the general population, combining them into what is known as a polygenic risk score (PRS). They also investigated the impact of rare genetic variants.
The polygenic risk score approach revealed that depending on the specific type of secondary cancer, genetic predisposition contributed between 5% and 37% of the risk. This finding challenges conventional wisdom, as Dr. Sapkota emphasized: "Our findings showed that genetics can be equally or more important than chemotherapy in some second cancers, which is counter to conventional wisdom in the field." This means that for certain secondary cancers, a survivor’s inherited genetic susceptibility can be as, or even more, influential than the specific chemotherapeutic agents they received.
Yutaka Yasui, PhD, also from St. Jude’s Department of Epidemiology and Cancer Control and a co-author, elaborated on the clinical potential of this approach: "Polygenic risk scores are developed for all kinds of diseases for personalized medicine, but generally with precision below what is required for clinical utility in the general population. Among survivors of childhood cancer and for estimating their risk of certain types of subsequent cancer, however, they may provide useful information in conjunction with therapy exposures." This suggests that while PRSs may have limited predictive power for the general population, their utility is significantly amplified within the context of childhood cancer survivors, where treatment exposures create a unique susceptibility landscape.
Lifestyle Factors: A Nuanced, Age-Dependent Influence
In contrast to treatment and genetic factors, lifestyle choices such as diet and exercise appeared to contribute much less to secondary cancer risk in this cohort, accounting for a modest 1% to 6% of the risk. However, the researchers cautioned against drawing definitive conclusions from this particular finding. The majority of survivors in the study were in their 20s and 30s, an age range where the long-term cumulative effects of lifestyle choices on cancer risk may not yet have fully manifested.
"We know healthy lifestyle choices are important for survivors," Dr. Sapkota clarified. "In this study, we focused only on the risk of second cancers, which may not be strongly impacted by lifestyle at this young age. However, other research has shown the benefits of healthy choices on other late effects, such as protecting cardiac wellbeing, so it is still important for clinicians to encourage — and patients to seek — a healthy lifestyle." This highlights the complexity of survivorship care, where different risk factors influence different late effects at different points in a survivor’s life.
Implications for Clinical Practice and Future Research
The findings from St. Jude represent a significant stride forward in understanding the complex etiology of secondary cancers in childhood cancer survivors, with profound implications for clinical practice, research, and patient empowerment.
Changing Care for Survivors of Childhood Cancer: A Personalized Approach
The most immediate and impactful implication is the urgent call for a paradigm shift in how secondary cancer risk is assessed and managed. "Historically, we have paid attention to survivors’ treatment exposures when determining second cancer risk," Dr. Sapkota stated. "Our study suggests that we need to better account for genetic predisposition in this population."
This means moving towards a more personalized, risk-stratified approach to long-term follow-up care. Survivors with identified genetic predispositions, particularly those with high polygenic risk scores for specific secondary cancers, could benefit from more regular and intensive cancer screenings. For example, a survivor with a genetic profile indicating increased risk for breast cancer might begin mammograms or MRIs earlier than standard guidelines suggest, or undergo them more frequently. The goal is early detection, when secondary cancers are often smaller, less advanced, and more responsive to treatment, thereby improving survival outcomes.
This knowledge also empowers survivors themselves. Armed with a comprehensive understanding of their unique combination of treatment-related, genetic, and lifestyle risk factors, patients can engage more proactively with their healthcare providers, advocating for tailored screening protocols and personalized risk reduction strategies.
Future Research Directions
The study opens numerous avenues for future research. Scientists will likely delve deeper into specific gene-treatment interactions, investigating how certain genetic variants modify the carcinogenic effects of particular chemotherapies or radiation fields. Further development and validation of clinically actionable polygenic risk scores are crucial, moving them from research tools to practical diagnostic aids. Longitudinal studies with even longer follow-up periods are needed to fully understand the evolving impact of lifestyle factors over a lifetime. Additionally, research into targeted preventative interventions for genetically predisposed survivors could revolutionize care.
Expert Perspectives and Broader Impact
The study’s findings are poised to influence clinical guidelines developed by major oncology organizations such as the Children’s Oncology Group (COG) and the American Society of Clinical Oncology (ASCO), which provide recommendations for the long-term follow-up of childhood cancer survivors. Incorporating genetic risk assessment into these guidelines would represent a significant advancement in survivor care.
Beyond the scientific and clinical communities, these findings will resonate deeply with patient advocacy groups and survivors themselves. Organizations dedicated to supporting childhood cancer survivors will likely champion the integration of genetic screening into standard follow-up care, ensuring that this crucial information is accessible and utilized to benefit patients. The ethical considerations of genetic testing, including potential psychological impact and issues of genetic discrimination, will also require careful consideration and policy development.
"Second cancers remain the leading cause of mortality for childhood cancer survivors," Dr. Sapkota reiterated, emphasizing the urgency of this research. "Now that we have quantified the contributions of treatment, genetics and lifestyle to the risk of secondary disease, we have a better understanding of where to focus efforts to prevent, detect and treat these cancers, and hopefully extend these survivors’ lives." This research marks a pivotal moment, offering a clearer roadmap to safeguarding the health of those who have already fought and won one of life’s toughest battles.
Authors and Funding
The study’s first author is Achal Neupane, of St. Jude. The study’s other authors include Siddhant Taneja, Jennifer French, Matthew Ehrhardt, Tara Brinkman, Rachel Webster, Jun Yang, Kirsten Ness, Melissa Hudson, Gregory Armstrong, Leslie Robison and Yutaka Yasui, all from St. Jude; Qi Liu from the University of Alberta; Cindy Im, Lucie Turcotte and Joseph Neglia from the University of Minnesota; Monica Gramatges from Baylor College of Medicine; Rebecca Howell from the University of Texas MD Anderson Cancer Center; and Smita Bhatia from the University of Alabama at Birmingham.
The study was supported by grants from the National Cancer Institute (R01HL173881, R01CA216354, R21CA261833, U24CA55727, U01CA195547 and CA21765) and ALSAC, the fundraising and awareness organization of St. Jude. This robust funding underscores the national commitment to improving the lives of childhood cancer survivors through rigorous scientific inquiry.